Bagremycin B is a natural product classified as an antibiotic, specifically belonging to the class of compounds known as anthracyclines. It is derived from microbial sources, exhibiting notable antibacterial properties. The chemical structure of Bagremycin B features a complex polycyclic framework, which is characteristic of many anthracycline antibiotics, contributing to its biological activity. This compound has been studied for its potential therapeutic applications, particularly in the treatment of various bacterial infections. Its mechanism of action typically involves interference with DNA replication and transcription, leading to cell death in susceptible organisms. Additionally, Bagremycin B may exhibit cytotoxic effects, making it a subject of interest in cancer research. As with many antibiotics, the efficacy and safety profile of Bagremycin B are critical for its potential use in clinical settings, necessitating further research to fully understand its pharmacological properties and therapeutic potential.

Bagremycin B

93316-63-3: Bagremycin B is a natural product classified as an antibiotic, specifically belonging to the class of compounds known as anthracyclines. It is derived from microbial sources, exhibiting notable antibacterial properties. The chemical structure of Bagremycin B features a complex polycyclic framework, which is characteristic of many anthracycline antibiotics, contributing to its biological activity. This compound has been studied for its potential therapeutic applications, particularly in the treatment of various bacterial infections. Its mechanism of action typically involves interference with DNA replication and transcription, leading to cell death in susceptible organisms. Additionally, Bagremycin B may exhibit cytotoxic effects, making it a subject of interest in cancer research. As with many antibiotics, the efficacy and safety profile of Bagremycin B are critical for its potential use in clinical settings, necessitating further research to fully understand its pharmacological properties and therapeutic potential.

<p>Bagremycin B is produced by the bacterium Streptomyces strain Tu 4128. It exhibits weak activity against Gram-positive bacteria, Saccharomyces cerevisiae, and Candida albicans.</p>

CAS 93316-63-3

Bagremycin B

Bagremycin B

Ref: TM-TN10692